CHE - Chemed Corporation

NYSE - Nasdaq Real Time Price. Currency in USD

317.05

+3.10 (+0.99%)

As of 1:11PM EDT. Market open.

Stock chart is not supported by your current browser

Previous Close	313.95
Open	314.87
Bid	316.99 x 1000
Ask	317.78 x 900
Day's Range	314.36 - 318.42
52 Week Range	191.39 - 335.99
Volume	36,986
Avg. Volume	129,055

Market Cap	5.101B
Beta	1.25
PE Ratio (TTM)	28.04
EPS (TTM)	11.31
Earnings Date	Oct 24, 2018 - Oct 29, 2018
Forward Dividend & Yield	1.20 (0.38%)
Ex-Dividend Date	2018-08-10
1y Target Est	330.50

Trade prices are not sourced from all markets

All

News

Press Releases

Zacks6 days ago
EHC or CHE: Which Is the Better Value Stock Right Now?
EHC vs. CHE: Which Stock Is the Better Value Option?
Markit14 days ago
See what the IHS Markit Score report has to say about Chemed Corp.
Chemed Corp NYSE:CHE
Simply Wall St.15 days ago
When Should You Buy Chemed Corporation (NYSE:CHE)?
Chemed Corporation (NYSE:CHE), a healthcare company based in United States, maintained its current share price over the past couple of month on the NYSE, with a relatively tight range ofRead More...
InvestorPlace19 days ago
4 Stocks to Bet on the Burgeoning Home Healthcare Industry
The home health industry is poised for tremendous growth driven by the growing geriatric U.S. population, the prevalence of chronic illness, high cost of treatment at inpatient settings and increased use of home healthcare technologies. Also, continued pressure on the U.S. healthcare system to control cost will lead to a shift in care from higher-cost institutional in patient care settings to a lower-cost environment such as home health and outpatient locations. Per Garden View Research, home healthcare is a cost efficient alternative to expensive hospital stays.
Zacks19 days ago
4 Stocks to Bet on the Burgeoning Home Healthcare Industry
Growing senior population, increasing chronic illness, high cost of treatment at inpatient settings and preference by patients drives demand for home health care.
Zacks22 days ago
EHC or CHE: Which Is the Better Value Stock Right Now?
EHC vs. CHE: Which Stock Is the Better Value Option?
Zackslast month
Chemed (CHE) Down 0.8% Since Last Earnings Report: Can It Rebound?
Chemed (CHE) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Zackslast month
Why You Should Add Chemed (CHE) Stock to Your Portfolio Now
Within Chemed's (CHE) VITAS business, management notes the recent admission trends to be consistently positive and this momentum is likely to continue.
Markitlast month
See what the IHS Markit Score report has to say about Chemed Corp.
Chemed Corp NYSE:CHE
Zackslast month
EHC vs. CHE: Which Stock Should Value Investors Buy Now?
EHC vs. CHE: Which Stock Is the Better Value Option?
Zacks2 months ago
STERIS (STE) Q1 Earnings & Revenues Beat Estimates, Up Y/Y
STERIS (STE) continues to gain from strength in all business segments in Q1.
Zacks2 months ago
Haemonetics (HAE) Q1 Earnings & Revenues Beat Estimates
Haemonetics' (HAE) year-over-year growth is backed by the solid execution of its multi-year turnaround strategy.
Zacks2 months ago
Wright Medical (WMGI) Beats on Q2 Earnings, Raises '18 View
Growth in the upper and lower extremity segments drives Wright Medical's (WMGI) Q2 results.
Zacks2 months ago
Bio-Rad (BIO) Tops Earnings and Revenue Estimates in Q2
Bio-Rad's (BIO) solid growth in North America, China and Asia Pacific reflects strong international foothold in Q2.
Markit2 months ago
See what the IHS Markit Score report has to say about Chemed Corp.
Chemed Corp NYSE:CHE
Zacks2 months ago
CVS Health's (CVS) Q2 Earnings Beat Estimate, Margins Up
CVS Health (CVS) reports strong Pharmacy Services revenues, benefiting from the upside in the specialty services. Year-over-year Retail/LTC comparisons are also encouraging.
Zacks2 months ago
BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Top
A shift in BioScrip's (BIOS) strategy and the impact of implementing ASC 606 induce a Q2 earnings miss for the company. However, its progress with the new multi-faceted CORE plan is a positive.
Zacks2 months ago
Penumbra (PEN) Q2 Earnings & Revenues Top Estimates, View Up
Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q2.
Markit2 months ago
See what the IHS Markit Score report has to say about Chemed Corp.
Chemed Corp NYSE:CHE
Zacks2 months ago
Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View
Surmodics' (SRDX) third-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.
Zacks2 months ago
Teleflex (TFX) Q2 Earnings Top, Sales Lag, '18 View Bearish
Teleflex (TFX) rides high on a strong year-over-year revenue improvement, banking on balanced segmental growth and wide geographical expansion.
Zacks2 months ago
Insulet (PODD) Q2 Loss Narrower Than Expected, Revenues Lag
We are encouraged by the year-over-year improvement in Insulet's (PODD) results on solid uptake of Omnipod system in the United States in Q2.
Zacks2 months ago
Luminex (LMNX) Misses on Earnings in Q2, Margins Contract
Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q2; a solid guidance encourages.
Markit2 months ago
See what the IHS Markit Score report has to say about Chemed Corp.
Chemed Corp NYSE:CHE
Zacks2 months ago
Henry Schein's (HSIC) Q2 Earnings Beat, '18 EPS View Up
All four of Henry Schein's (HSIC) operating segments recorded strong year-over-year growth in Q2.